<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857805</url>
  </required_header>
  <id_info>
    <org_study_id>58348</org_study_id>
    <nct_id>NCT00857805</nct_id>
  </id_info>
  <brief_title>Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma</brief_title>
  <official_title>Randomized Controlled Trial of Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with liver tumor burden that exceeds Milan criteria are considered to receive one of&#xD;
      the following locoregional treatments: transarterial chemoembolization (TACE), radiofrequency&#xD;
      ablation (RFA), percutaneous ethanol injection and proton beam radiation (PBR). The goals of&#xD;
      these treatments are to control tumor growth, to downstage tumor size to meet Milan criteria,&#xD;
      and to improve survival. Patients who exceed the Milan criteria benefit from tumor&#xD;
      downstaging as a result of treatment. Patients who meet Milan criteria benefit from tumor&#xD;
      control to bridge them to liver transplantation. TACE is considered the most common&#xD;
      locoregional treatment that is used to treat hepatocellular carcinoma (HCC). Proton beam&#xD;
      radiotherapy has been used in treating HCC in a few centers across the globe. Phase I and II&#xD;
      trials showed a satisfactory safety and efficacy results. Loma Linda University Medical&#xD;
      Center is one of these pioneering centers that use proton beam as a treatment for HCC. This&#xD;
      is the first randomized trial in the medical field that will compare head-to-head the&#xD;
      efficacy of TACE versus proton beam in treating HCC patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2009</start_date>
  <completion_date type="Actual">July 7, 2021</completion_date>
  <primary_completion_date type="Actual">July 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>lifetime</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Lifetime</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Downstaging</measure>
    <time_frame>Lifetime</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Transarterial Chemoembolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transarterial Chemoembolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proton Beam Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proton Beam Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial Chemoembolization</intervention_name>
    <description>Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.</description>
    <arm_group_label>Transarterial Chemoembolization</arm_group_label>
    <other_name>(TACE)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Beam Radiotherapy</intervention_name>
    <description>Fifteen consecutive sessions</description>
    <arm_group_label>Proton Beam Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients are candidates to receive both proton beam and TACE&#xD;
&#xD;
          2. Patients with no evidence of metastasis or macrovascular invasion&#xD;
&#xD;
          3. Patients with tumor burden that meets San Francisco criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are candidates for surgical resection&#xD;
&#xD;
          2. Patients with lesion &lt; 2 cm&#xD;
&#xD;
          3. Patients who have contraindication to receive either TACE or proton&#xD;
&#xD;
          4. Patients with serum alpha fetoprotein &gt; 500&#xD;
&#xD;
          5. Patients with metastasis or macrovascular invasion&#xD;
&#xD;
          6. Patients treated previously for HCC by any locoregional treatment&#xD;
&#xD;
          7. Patients with prior liver transplant&#xD;
&#xD;
          8. Patients with Child class C&#xD;
&#xD;
          9. Patients with MELD score of &gt; 25&#xD;
&#xD;
         10. Patients with other comorbid diseases that may impact survival&#xD;
&#xD;
         11. Patients with ongoing alcohol intake&#xD;
&#xD;
         12. Patients with active sepsis&#xD;
&#xD;
         13. Patients with gastrointestinal bleeding within a week&#xD;
&#xD;
         14. Patients unwilling to sign informed consent form&#xD;
&#xD;
         15. Patients with history of noncompliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael deVera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transarterial chemoembolization</keyword>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>Proton Beam Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

